The Effects of NMN on Blood Pressure

NMN (nicotinamide mononucleotide) supplementation appears to have a modest lowering effect on blood pressure, with the most consistent human evidence pointing to a drop of about 2 mmHg in diastolic pressure across several randomized controlled trials. The effect is not dramatic for the average healthy adult, but it becomes more pronounced in specific groups, particularly people over 60 and those already diagnosed with hypertension. What makes NMN’s influence on cardiovascular health more interesting than a single blood pressure number, though, is the growing evidence that it affects the blood vessels themselves in ways that go beyond what a cuff reading captures.

What the Human Trials Show

The broadest look at NMN and blood pressure comes from a systematic review and meta-analysis that pooled results from multiple randomized controlled trials. The analysis found that NMN supplementation reduced resting diastolic blood pressure by about 2 mmHg compared with placebo. The reduction in systolic blood pressure, however, did not reach statistical significance when all participants were lumped together.¹ A 2 mmHg shift in diastolic pressure sounds trivial at the individual level, but at a population scale, even small reductions in average blood pressure translate into meaningful reductions in stroke and heart disease risk. That said, this is not the kind of result that would replace a blood pressure medication.

More striking results came from a small trial focused specifically on hypertensive patients. Nine adults took 800 mg of NMN daily for six weeks alongside lifestyle modifications, while ten others made lifestyle changes alone. The NMN group saw systolic blood pressure drop by about 6 mmHg and diastolic by roughly 3.5 mmHg, and their blood vessel function improved measurably as well.² The catch is that this was an extremely small trial, so the numbers carry wide uncertainty. They do suggest that NMN has its strongest blood-pressure-lowering potential in people who already have elevated readings, which aligns with how many cardiovascular interventions work: the further from normal you start, the more room there is to improve.

In healthy adults with normal blood pressure, the picture is quieter. A 12-week placebo-controlled trial of 250 mg per day of NMN in healthy middle-aged adults showed no significant changes in vital signs, including blood pressure, between the NMN and placebo groups.³ If your blood pressure is already healthy, NMN is unlikely to push it lower in a way you would notice.

Older Adults and Those With Risk Factors Respond Differently

The meta-analysis mentioned above included a subgroup analysis by age, and the results are worth paying attention to. Among participants aged 60 and older, NMN supplementation produced a significant reduction in systolic blood pressure of about 4 mmHg, an effect that vanished when younger adults were included in the calculation.¹ This fits neatly with what is known about NAD+ levels: they decline substantially with age, and the downstream effects of that decline, including stiffer arteries and less responsive blood vessels, are more pronounced in older people. Replenishing what has been lost makes more of a difference when the starting deficit is larger.

Metabolic status matters too. In the arterial stiffness trial of healthy middle-aged adults, researchers found no overall difference in pulse wave velocity (a measure of how stiff your arteries are) between NMN and placebo groups. But when they looked specifically at participants who had above-average body mass index or blood glucose levels, the NMN group showed a significant decrease in arterial stiffness.³ People carrying extra weight or running higher blood sugar have more oxidative stress and inflammation in their blood vessels, which are exactly the processes NMN targets through its metabolic pathways. In someone whose vasculature is already under strain, restoring NAD+ levels has more to work with.

For people with diagnosed hypertension, the small trial described earlier showed the most dramatic changes, including improvements in flow-mediated dilation (a marker of how well your arteries relax when blood flow increases) and a large decrease in pulse wave velocity.² The pattern across all these trials is consistent: NMN’s blood pressure effects are not uniform across everyone, and they concentrate in the populations where vascular dysfunction is already present.

Vascular Health Beyond the Blood Pressure Cuff

Blood pressure is just one readout of cardiovascular health, and some of NMN’s most interesting effects show up in the blood vessels themselves. Arterial stiffness, measured by pulse wave velocity, reflects how flexible your artery walls are. Stiff arteries force the heart to work harder and contribute to isolated systolic hypertension, the most common form of high blood pressure in older adults. In the hypertension trial, NMN reduced pulse wave velocity by about 117 cm/s over six weeks, a meaningful improvement.²

Animal studies add further texture. In mice given angiotensin II (a hormone that constricts blood vessels and raises blood pressure), oral NMN reduced the thickening of the arterial wall by about a quarter and restored elastic fiber content, essentially reversing some of the structural remodeling that high blood pressure causes.⁴ Vascular remodeling is a big deal in chronic hypertension because once the artery walls physically thicken and stiffen, lowering blood pressure alone does not fully undo the damage. If NMN helps prevent or reverse that remodeling, that would be a benefit that goes beyond what a blood pressure reading captures.

In aged mice, NMN also restored capillary density in skeletal muscle to levels typically seen in young animals, improved resting blood flow, and increased blood oxygen levels. The most dramatic result was an improvement in running endurance of somewhere between 56% and 80%.⁵ These are the kinds of vascular changes that, if they translate to humans, would explain why NMN might improve cardiovascular health even when the blood pressure cuff does not register a large shift.

How NMN Affects Blood Vessel Function

The leading explanation for NMN’s cardiovascular effects centers on what happens inside the endothelium, the thin layer of cells lining every blood vessel. These cells produce nitric oxide, a molecule that signals surrounding muscle to relax, widening the vessel and lowering pressure. With age, endothelial cells produce less nitric oxide, partly because NAD+ levels fall and the enzymes that depend on NAD+ stop working as well.

In aged mice, NMN supplementation for two weeks restored neurovascular coupling, the process by which increased brain activity triggers local blood flow increases, back to levels seen in young animals. Blocking nitric oxide production erased the benefit, confirming that NMN was working through the nitric oxide pathway.⁶ The same animals showed improved spatial memory and coordination, suggesting that better blood vessel function in the brain has cognitive payoffs too.

Oxidative stress is the other half of the story. When cells produce too many reactive oxygen species and cannot neutralize them, the damage hits endothelial cells especially hard. NMN treatment in isolated aortas from aged mice increased levels of manganese superoxide dismutase, a key antioxidant enzyme, by about 50%.⁷ In cell culture, NMN prevented the structural disorganization that hydrogen peroxide causes in endothelial cells by suppressing reactive oxygen species production.⁸ And in aged cerebromicrovascular endothelial cells isolated from rats, NMN improved the cells’ ability to proliferate, migrate, and form capillary-like tubes, while reducing hydrogen peroxide production.⁹

These mechanisms tie together: NMN raises NAD+, which activates the SIRT1 enzyme, which promotes endothelial cell survival, nitric oxide production, new blood vessel formation, and antioxidant defense.¹⁰ The blood pressure changes observed in humans are likely downstream of these processes. The vessels relax more easily, resist oxidative damage better, and maintain their structure, all of which contribute to lower resistance and, eventually, lower pressure readings.

Why Duration and Dose Matter

One point that trips people up is expecting NMN to work like a fast-acting blood pressure drug. In a study using spontaneously hypertensive rats (a breed that develops high blood pressure naturally), a single dose of 200 mg/kg of NMN produced no change in systolic pressure, diastolic pressure, mean arterial pressure, or heart rate within two hours.¹¹ This makes biological sense: NMN is not a vasodilator in the traditional pharmaceutical sense. It is a precursor to NAD+, which then gradually supports enzyme activity, gene expression, and cellular repair processes that take days to weeks to meaningfully shift vascular function.

The human trials that showed blood pressure effects used daily supplementation for at least six weeks, and the arterial stiffness trial ran for 12 weeks. Dosing in human studies has ranged from 250 mg to 800 mg per day, with the larger effects on blood pressure coming from the higher dose used in hypertensive patients.² Whether higher doses consistently produce larger blood pressure reductions is not yet clear from the available data. The 250 mg dose used in the arterial stiffness trial did not significantly affect blood pressure in healthy middle-aged adults, but it did improve arterial stiffness in higher-risk subgroups, suggesting even lower doses may have vascular benefits that do not show up as blood pressure changes.

Safety at Current Doses

NMN has a reassuring safety profile in the trials conducted so far. A study evaluating single oral doses of up to 500 mg in healthy adults found no harmful effects and no changes in heart rate, blood pressure, oxygen saturation, or body temperature.¹² The 12-week trial using 250 mg daily similarly found no significant changes in blood chemistry, hematology, or hormone levels, and no adverse events attributable to NMN.³

One practical concern is whether NMN might lower blood pressure too much in people who are already on antihypertensive medications. The current data does not flag this as a problem. In the healthy-adult trials, blood pressure barely moved at all. In the hypertensive trial, the reductions were moderate, not the steep drops that would signal hypotension risk. But the trials were small, and people taking multiple blood pressure drugs were not well represented. If you are on medication for hypertension and considering NMN, it is worth discussing with your doctor so they can monitor for any additive effect.

How NMN Compares to Nicotinamide Riboside

NMN is not the only NAD+ precursor supplement on the market. Nicotinamide riboside (NR) is a closely related molecule that also raises NAD+ levels, and it has been tested for blood pressure effects as well. A pilot trial combined NR supplementation with exercise in hypertensive middle-aged and older adults. The group taking NR plus exercising did not lower systolic blood pressure more than the group taking placebo plus exercising. There was a trend toward reduced arterial stiffness in the NR group, and a post-hoc analysis found a trend toward larger nighttime blood pressure reductions in NR users who were not already on antihypertensive medication, but neither finding was statistically significant.¹³

The NR trial’s results are not directly comparable to NMN results, because both arms included exercise, making it harder to isolate the supplement’s contribution. But the overall pattern is similar across both molecules: NAD+ precursors show suggestive but inconsistent effects on blood pressure, with the clearest signals in people who have more vascular dysfunction to begin with. Neither NMN nor NR has produced the kind of large, consistent blood pressure reductions that would position them as replacements for standard antihypertensive therapies. They may be more useful as adjuncts that address the underlying vascular biology rather than as direct blood-pressure-lowering agents.

NMN, the Renin-Angiotensin System, and Kidney Health

An unexpected thread connects NMN to blood pressure regulation through the kidneys. In a metabolomic study of patients with chronic kidney disease, researchers identified NMN (the molecule as it appears in the bloodstream, not as a supplement) as a potential biomarker. They found abnormal NMN expression in these patients and linked it to activation of the renin-angiotensin system, the hormonal cascade that is the primary target of ACE inhibitors and angiotensin receptor blockers.¹⁴

This is not about supplementation. It is about how NMN metabolism in the body may serve as a window into kidney-related blood pressure problems. The kidneys are central to long-term blood pressure control because they regulate sodium and water balance, and the renin-angiotensin system is how they communicate with the rest of the cardiovascular system. The fact that NMN levels are disrupted in kidney disease patients raises the possibility that NAD+ metabolism is entangled with blood pressure regulation in ways beyond the vascular-wall effects described earlier. Whether supplemental NMN could meaningfully interact with these kidney-level pathways in humans remains unknown, but it is a direction that future research will likely explore.

What NMN Will Not Do for Blood Pressure

The evidence, taken together, paints a picture of a supplement with real but limited blood-pressure-lowering ability. A few things NMN clearly will not do, based on what the trials show. It will not produce a fast drop in blood pressure after a single dose. It will not significantly lower systolic pressure in young, healthy people. It will not replace medications in someone with stage 2 hypertension. And it will not work the same way in everyone: the people most likely to see blood pressure changes are those whose vascular health is already compromised by age, metabolic risk factors, or diagnosed hypertension.

Where NMN looks more promising is as a long-term vascular health intervention that may protect arterial flexibility, improve endothelial function, and reduce oxidative stress in blood vessel walls. These changes may or may not show up as a lower number on the blood pressure cuff on any given day, but they matter for cardiovascular risk over years and decades. The research is still young, the trials are small, and the field needs larger, longer studies before anyone should consider NMN a serious tool for blood pressure management. For now, it is a biologically plausible supplement with early-stage evidence, not a proven therapy.